Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Status:
Suspended
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603
in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases. The
study drug will be administered by intravenous infusion.